U.S. Markets closed

Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

Arpita Dutt

Several important developments were reported this week with key highlights including the termination of a hepatitis C virus deal, the approval of the first cancer biosimilar in the United States and the presentation of data by companies like Pfizer PFE and Bristol-Myers Squibb BMY among others.

Recap of the Week’s Most Important Stories

Achillion Down on HCV Deal Termination: Achillion Pharmaceuticals’s ACHN shares fell on the termination of the company’s partnership agreement with Johnson & Johnson’s Janssen Pharmaceuticals for hepatitis C virus ("HCV"). Janssen said that it will not continue with the development of JNJ-4178, a combination of three direct acting antivirals: AL-335, odalasvir and simeprevir. The decision to discontinue development does not come as a big surprise given the intense competition and pricing dynamics in the HCV market. Achillion intends to focus on the development of advanced multiple small molecule factor D inhibitors of the complement alternative pathway (Read more: Achillion's HCV Partnership with J&J Terminated, Stock Falls).

First Cancer Biosimilar Gets FDA Nod: The FDA approved Allergan AGN and Amgen’s Mvasi, a biosimilar version of Roche’s blockbuster cancer drug, Avastin (bevacizumab). Mvasi can be used for all eligible indications of the reference product. Approval was in line with expectations considering the favorable vote the biosimilar got from an FDA advisory panel recently. The approval is quite a boost for the companies as well as the effort to lower drug prices though so far biosimilars are yet to make a significant dent in referenced product sales in the United States. Mvasi is under review in the EU.

Pfizer’s Xtandi PROSPERs in Late-Stage Study: Pfizer and partner Astellas Pharma could well be on the path to boost sales of their prostate cancer drug, Xtandi, with the companies announcing positive top-line data from a late-stage study (PROSPER) in patients with non-metastatic (M0) castration-resistant prostate cancer ("CRPC"). The companies plan to discuss this data with regulatory authorities for the expansion of the drug’s label. Xtandi sales, which have been under pressure, should receive a boost on approval for this patient population.

Bristol-Myers Signs Deal, Presents Cancer Data: Bristol-Myers Squibb presented data at the European Society for Medical Oncology ("ESMO") 2017 Congress showing that treatment with Opdivo led to superior recurrence-free survival (35%) compared to Yervoy in patients with resected high-risk melanoma (Read more: Bristol-Myers Reports Positive Results from Melanoma Study).

Meanwhile, the company has signed a deal with Halozyme for the latter’s ENHANZE technology. The global collaboration and license agreement is focused on the use of Halozyme’s technology for the subcutaneous administration of Bristol-Myers’s immuno-oncology drugs thereby providing patients with more flexible and convenient treatment delivery options.

Bristol-Myers will shell out $105 million upfront plus make future milestone and royalty payments. The dilutive transaction is expected to hit Bristol-Myers’s 2017 and 2018 earnings by a penny and 2019 earnings by five cents.

Lilly’s Baricitinib Fares Well in Mid-Stage Eczema Study: Eli Lilly and Company LLY and Incyte presented new safety and efficacy data from a mid-stage study on baricitinib for eczema at the annual meeting of the European Academy of Dermatology and Venereology ("EADV"). Baricitinib, when combined with a mid-potency topical corticosteroid ("TCS"), significantly improved the signs and symptoms of eczema compared to TCS alone. The companies intend to commence a phase III program for the eczema indication later this year. Baricitinib is currently approved in the EU under the trade name Olumiant for moderate-to-severe-active rheumatoid arthritis. However, approval is yet to come in the United States where a regulatory filing will be resubmitted by Jan 2018. Lilly stock has gained 12.9% year to date, compared to the 16% rally of the industry it belongs to.

Teva Appoints New CEO: Teva TEVA has finally ended its search for a Chief Executive Officer (“CEO”) with the company announcing the appointment of Kare Schultz as the company’s President and CEO. A seasoned veteran in the healthcare industry, Schulz will bring with him almost thirty years of experience in this segment. Schulz was recently serving as the President and CEO of H. Lundbeck A/S, where he was responsible for implementing significant restructuring initiatives and launching a robust turnaround strategy. Schulz has a daunting task ahead of him considering the challenges being faced by Teva including generic pricing erosion. The company needs to work on paying down debt, divesting non-core businesses to increase focus on core areas and generate cash, delivering on the pipeline and getting the U.S. generics business back on track (Read more: Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?).

Positive FDA Panel Vote for Glaxo’s Shingles Vaccine: GlaxoSmithKline GSK got a positive vote from the FDA’s Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) for Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over. Given the positive vote, chances of gaining approval look pretty high. We note that Merck’s Zostavax, a live attenuated virus vaccine is currently available for the prevention of shingles in the same patient population (Read more: Glaxo's Shingles Candidate Gets Positive FDA Committee Vote).

Glaxo is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Large Cap Pharmaceuticals Industry 5YR % Return

Large Cap Pharmaceuticals Industry 5YR % Return

The NYSE ARCA Pharmaceutical Index was up 2% over the last five trading sessions. Almost all major stocks recorded gains with Pfizer gaining 5.1% while Bristol-Myers slipped 0.2%. Over the last six months, Bristol-Myers was up 12.2% while Glaxo declined 0.9% (See the last pharma stock roundup here: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018).

What's Next in the Pharma World?

Watch out for the usual pipeline and regulatory updates. An FDA advisory panel will be meeting on Sep 19 to discuss the supplemental new drug application (sNDA) submitted by Pfizer for its cancer drug, Sutent, for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (“RCC”) following nephrectomy (surgical removal of the cancer-containing kidney). Moreover, an FDA decision regarding the label expansion of Merck’s anti-PD-1 therapy, Keytruda, for use in the treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma, should be out by Sep 22.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.   

See the pot trades we're targeting>>                              

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Pfizer, Inc. (PFE) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Allergan PLC. (AGN) : Free Stock Analysis Report
GlaxoSmithKline PLC (GSK) : Free Stock Analysis Report
Achillion Pharmaceuticals, Inc. (ACHN) : Free Stock Analysis Report
Teva Pharmaceutical Industries Limited (TEVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

  • Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?
    Market Realist

    Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?

    Tesla (TSLA) stock appears to be defying gravity today and is rallying despite the broader market sell-off. Today at 1:08 PM EDT, Tesla stock was up 10.2% from the previous session’s closing price. Earlier today, Citron Research—one of the Tesla bears—surprised the market by turning positive on TSLA for the first time.

  • News

    American Electric Power boosts dividend 8.1% to push yield above utilities sector's

    MARKET PULSE American Electric Power Co. Inc. (aep) said Tuesday it will raise its quarterly dividend by 8.1% to 67 cents a share from 62 cents a share. The new dividend will be payable Dec. 10 to shareholders of record on Nov. 9. The

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • Companies Say They're Ready to Move Supply Chains From China

    Companies Say They're Ready to Move Supply Chains From China

    U.S. President Donald Trump imposed a 10 percent tariff on $200 billion of Chinese imports in September -- following an earlier round of tariffs on $50 billion of goods -- and promised to raise the duty to 25 percent in January. "We’re pro-actively taking action," Todd Bluedorn, chief executive officer of the Texas-based HVAC company, told analysts during an Oct. 22 earnings call.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • Business

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • MARKETS: Here's why stocks are selling off right now and what a bottom would look like
    Yahoo Finance Video

    MARKETS: Here's why stocks are selling off right now and what a bottom would look like

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

  • News

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • These stocks may be sacrificed in a cold war with China
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • Business
    Motley Fool

    Parsing Visa's Big Quarterly Dividend Hike

    The ubiquitous financial services player Visa (NYSE: V) isn't exactly an income stock -- its dividend yield has fairly consistently been below 1% for years. Which raises two interesting questions for MarketFoolery host Chris Hill and senior analyst Jason Moser. In this segment from MarketFoolery, they discuss Visa's cash cow structure, its stock repurchases, and the M&A possibilities it thus far seems to be ignoring.

  • Why Senseonics Holdings Inc. Is Soaring Today
    Motley Fool

    Why Senseonics Holdings Inc. Is Soaring Today

    In response to signing a reimbursement contract with one of the largest insurers in the U.S., shares of Senseonics Holdings (NYSEMKT: SENS), a medical device company focused on blood sugar monitoring, rose 11% as of 10:30 a.m. EDT on Tuesday. Senseonics announced today that Aetna (NYSE: AET) is now offering reimbursement for the company's recently approved Eversense Continuous Glucose Monitoring System (CGM). This is a big deal for Senseonics because Aetna is the third-largest health insurer in the U.S. with more than 22 million lives covered.

  • Business

    Morgan Stanley: 6 Ways Caesars Entertainment Can Create Value

    Gaming operator Caesars Entertainment Corporation (NASDAQ: CZR) boasts multiple upside catalysts that imply the stock is undervalued, according to Morgan Stanley. The Analyst Morgan Stanley's Thomas Allen initiated coverage of Caesars Entertainment 

  • Is the New Energy Transfer LP a Buy?
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to $82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

  • What to Expect from Bristol-Myers Squibb’s Q3 Earnings
    Market Realist

    What to Expect from Bristol-Myers Squibb’s Q3 Earnings

    Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from $5.25 billion in the third quarter of 2017 to $5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.

  • Caterpillar's Q3 beat expectations, shares tumble
    Yahoo Finance

    Caterpillar's Q3 beat expectations, shares tumble

    A Caterpillar Inc. equipment is on display for sale at a retail site in San Diego, California, U.S., March 3, 2017. Global construction equipment giant Caterpillar (CAT) announced quarterly results that were a bit better than expected. Caterpillar’s construction industries business segment sales grew 16% to $5.7 billion.

  • Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

    Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

    It was a punishing start for stocks Tuesday as investors reacted negatively to quarterly results from a handful of blue chips and the cessation of a two-day rebound for China’s embattled stock market, reviving fresh questions about global economic growth prospects. The Dow Jones Industrial Average (DJIA) 548.62 points at its low and remained was recently 460 points, or 1.8%, at 24,862. The S&P 500 (SPX) fell 55 points, or 2%, to 2,696, retreating below a psychological and technical mark at 2,700, while the Nasdaq Composite Index (COMP) slid gave up 177 points, or 2.4%, to 7,291.

  • What the Market Missed in Kinder Morgan Inc.'s Results
    Motley Fool

    What the Market Missed in Kinder Morgan Inc.'s Results

    Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

  • Business

    A Preview Of Juniper Networks Q3 Earnings

    Juniper Networks (NYSE: JNPR) releases its next round of earnings this Tuesday, Oct. 23. Here's Benzinga's essential guide to Juniper Networks' Q3 earnings report. Earnings and Revenue Juniper Networks EPS will likely be near 44 cents while revenue will

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.